Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9497 - 9504 of 11621 results
Enactment Imminent for Section 529A Tax-Exempt Savings Programs for Disabled Beneficiaries
December 17, 2014| Blog| Viewpoint
The Affordable Care Act—Countdown to Compliance for Employers, Week 2: Explaining the Look-Back Measurement Method to Employees
December 16, 2014| Blog| Viewpoint
EEOC's Attempt to Limit Reach of Severance Agreements Hits Roadblock… Again
December 16, 2014| Blog| Viewpoint
Supreme Court Finds that Post-Shift Employee Security Screenings Noncompensable Activity Under the Fair Labor Standards Act
December 16, 2014| Blog| Viewpoint
On the Sixth Day of Privacy, the hackers gave to Sony......
December 16, 2014| Blog| Viewpoint
Back at it Again: NLRB Invalidates Employer’s “Overbroad” Solicitation Rule
December 15, 2014| Blog| Viewpoint
Staffing Companies Hit with Class Action Alleging Violation of Fair Credit Reporting Act
December 15, 2014| Blog| Viewpoint
For the First Time PTAB Upholds Validity of Pharma Patents
December 15, 2014| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.